Mesalazine Aurobindo

Mesalazine, the active ingredient in Mesalazine Aurobindo, is an aminosalicylate presented as a rectal formulation for rectal use. It treats ulcerative colitis and colonic Crohn's disease in adult patients, helping to induce and maintain remission. GNH USA supplies Mesalazine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazine is an aminosalicylate used to manage inflammatory bowel disease. - Ulcerative colitis: induction of remission and control of disease activity. - Ulcerative colitis (maintenance): helps maintain remission after induction therapy. - Colonic Crohn's disease: used for maintenance therapy to reduce flare frequency.

Mesalazine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Abdominal pain or cramping. - Diarrhea or loose stools. - Nausea or mild vomiting. - Headache. - Rectal irritation or burning. - Flatulence.

Serious or Rare Side Effects: - Severe allergic reactions such as rash, angioedema, or anaphylaxis. - Hepatotoxicity manifested by elevated liver enzymes. - Blood dyscrasias including neutropenia or thrombocytopenia. - Pancreatitis. - Worsening of colitis or new onset colonic ulceration. - Interstitial nephritis or renal impairment.

Before initiating therapy, clinicians should consider several safety measures. - Renal function monitoring: assess baseline creatinine and periodically re‑check. - Hepatic function monitoring: evaluate liver enzymes before and during treatment. - Hypersensitivity assessment: avoid use in patients with known salicylate allergy. - Severe disease caution: use with care in patients with fulminant ulcerative colitis. - Concomitant anticoagulant use: monitor for increased bleeding risk. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mesalazine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Warfarin or other anticoagulants: increased risk of bleeding. - Live vaccines: potential for reduced vaccine efficacy and infection. - Sulfasalazine: additive toxicity, especially hematologic effects.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may heighten renal toxicity. - Azathioprine or 6‑mercaptopurine: possible additive bone‑marrow suppression. - Oral contraceptives: mesalazine may reduce hormonal efficacy, requiring alternative contraception.